- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 3.00 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x UMP: 2'-DEOXYURIDINE 5'-MONOPHOSPHATE(Non-covalent)
- 2 x NDP: NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)
NDP.2: 28 residues within 4Å:- Chain A: V.9, A.10, I.17, G.18, I.19, N.21, G.22, L.23, W.25, G.55, R.56, K.57, T.58, S.61, V.77, S.78, S.79, S.80, A.103, V.126, G.127, G.128, A.129, G.130, L.131, Y.132, V.157
- Ligands: K9A.4
20 PLIP interactions:20 interactions with chain A- Hydrophobic interactions: A:T.58
- Hydrogen bonds: A:A.10, A:I.17, A:I.19, A:G.55, A:R.56, A:R.56, A:K.57, A:T.58, A:T.58, A:S.61, A:S.61, A:S.79, A:S.80, A:G.128, A:A.129, A:G.130, A:G.130, A:L.131
- Salt bridges: A:R.56
NDP.7: 29 residues within 4Å:- Chain B: V.9, A.10, I.17, G.18, I.19, N.21, G.22, L.23, W.25, G.55, R.56, K.57, T.58, S.61, V.77, S.78, S.79, S.80, A.103, S.104, V.126, G.128, A.129, G.130, L.131, Y.132, A.134, V.157
- Ligands: K9A.9
18 PLIP interactions:18 interactions with chain B- Hydrophobic interactions: B:T.58
- Hydrogen bonds: B:A.10, B:I.17, B:I.19, B:G.55, B:R.56, B:K.57, B:K.57, B:T.58, B:S.61, B:S.61, B:S.79, B:S.80, B:G.128, B:A.129, B:G.130, B:L.131
- Salt bridges: B:R.56
- 2 x CB3: 10-PROPARGYL-5,8-DIDEAZAFOLIC ACID(Non-covalent)
CB3.3: 17 residues within 4Å:- Chain A: K.327, R.328, V.329, F.330, E.337, I.358, N.362, D.469, L.472, G.473, F.476, N.477, Y.509, R.559, M.564, A.565
- Ligands: UMP.1
15 PLIP interactions:15 interactions with chain A- Hydrophobic interactions: A:F.330, A:I.358, A:I.358, A:F.476
- Hydrogen bonds: A:R.328, A:F.330, A:D.469, A:Y.509, A:A.565, A:A.565, A:A.565
- Salt bridges: A:K.327, A:D.469, A:R.559
- pi-Stacking: A:F.476
CB3.8: 16 residues within 4Å:- Chain B: K.327, R.328, V.329, F.330, I.358, N.362, D.469, L.472, G.473, F.476, N.477, Y.509, R.559, M.564, A.565
- Ligands: UMP.6
15 PLIP interactions:15 interactions with chain B- Hydrophobic interactions: B:F.330, B:I.358, B:I.358, B:L.472, B:F.476, B:F.476
- Hydrogen bonds: B:F.330, B:D.469, B:L.472, B:A.565, B:A.565, B:A.565
- Salt bridges: B:K.327, B:D.469, B:R.559
- 2 x K9A: 5-{4-[3-(2-methylpyrimidin-5-yl)phenyl]piperazin-1-yl}pyrimidine-2,4-diamine(Non-covalent)
K9A.4: 16 residues within 4Å:- Chain A: V.8, V.9, A.10, L.23, H.27, D.31, F.32, F.35, M.62, P.63, F.66, V.126, Y.132, T.147
- Ligands: NDP.2, EDO.5
8 PLIP interactions:8 interactions with chain A- Hydrophobic interactions: A:F.32, A:F.66
- Hydrogen bonds: A:V.8, A:A.10, A:Y.132, A:T.147, A:T.147
- Salt bridges: A:D.31
K9A.9: 15 residues within 4Å:- Chain B: V.8, V.9, A.10, L.23, H.27, D.31, F.32, F.35, M.62, P.63, F.66, V.126, Y.132, T.147
- Ligands: NDP.7
7 PLIP interactions:7 interactions with chain B- Hydrophobic interactions: B:F.32, B:F.66
- Hydrogen bonds: B:V.8, B:V.9, B:Y.132, B:T.147
- Salt bridges: B:D.31
- 1 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Hopper, A.T. et al., Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J. Med. Chem. (2019)
- Release Date
- 2019-01-23
- Peptides
- Bifunctional dihydrofolate reductase-thymidylate synthase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 3.00 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x UMP: 2'-DEOXYURIDINE 5'-MONOPHOSPHATE(Non-covalent)
- 2 x NDP: NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)
- 2 x CB3: 10-PROPARGYL-5,8-DIDEAZAFOLIC ACID(Non-covalent)
- 2 x K9A: 5-{4-[3-(2-methylpyrimidin-5-yl)phenyl]piperazin-1-yl}pyrimidine-2,4-diamine(Non-covalent)
- 1 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Hopper, A.T. et al., Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J. Med. Chem. (2019)
- Release Date
- 2019-01-23
- Peptides
- Bifunctional dihydrofolate reductase-thymidylate synthase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B